Art. -Nr.: HY-114363A

SRI 31215 TFA

Name: SRI 31215 TFA
Brand: MedChemExpress
SKU: HY-114363A
Price: 180.00 USD
Availability: InStock
Rating: 5 (2 reviews)

2 Cited Publications

Kundenbewertung

Based on 2 publication(s) in Google Scholar

SRI 31215 (TFA) is a Matriptase/Hepsin/hepatocyte growth factor activator (HGFA) triplex inhibitor and mimics the activity of HAI-1/2 (endogenous inhibitors of HGF activation). SRI 31215 has potent inhibitory activity against matriptase, hepsin and HGFA with IC₅₀ values of 0.69 μM, 0.65 μM and 0.30 μM, respectively. SRI 31215 can be used for the research of cancer.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit : 98.35%
CAS. Nr.: 1832686-44-8
Formel: C₂₇H₃₄F₃N₅O₃
Molecular Weight:533.59

Speicherung:

4°C, sealed storage, away from moisture

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

SRI 31215 TFA Chemical Structure

CAS. Nr.: 1832686-44-8

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- In Vitro
Chemical Information
Publications (2)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target

IC50: 0.69 μM (matriptase); 0.65 μM (hepsin); 0.30 μM (HGFA)^[1]

In Vitro

SRI 31215 (TFA) has potent activity against matriptase, hepsin and HGFA with IC₅₀ values of 0.69 μM, 0.65 μM and 0.30 μM, respectively^[1].
SRI 31215 (10 μM) inhibits the proteolytic activation of pro-HGF^[1].
SRI 31215 (10 μM, 30 min) inhibits fibroblast-induced HGF/MET signaling in tumor cells^[1].
SRI 31215 (10 μM, 24 h) inhibits fibroblast-induced epithelial mesenchymal transition (EMT) and migration in tumor cells^[1].
SRI 31215 (10 μM) overcomes the resistance to EGFR inhibitors mediated by autocrine HGF/MET signaling in colon cancer cells^[1].
SRI31215 (10 μM, 72 h) averts fibroblast-mediated resistance to EGFRi-induced apoptosis^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[1]

Cell Line:

DU145 cells
Concentration:

10 μM
Incubation Time:

30 min
Result:

Prevented fibroblast-induced MET activation and signaling in tumor cells, but did not prevent MET activation induced by active HGF.

Cell Migration Assay ^[1]

Cell Line:

DU145 cells
Concentration:

10 μM
Incubation Time:

24 h
Result:

Did not interfere with HGF-induced migration, but inhibited fibroblast-induced migration of DU145 cells.

Chemical Information

CAS. Nr. 1832686-44-8
Appearance Solid
Molecular Weight 533.59
Formel C₂₇H₃₄F₃N₅O₃
Color Light yellow to khaki
SMILES

N=C(C1=CC=CC(N2CC(C)CN(CC3CCN(CC4=CC=CC=C4)CC3)C2=O)=C1)N.OC(C(F)(F)F)=O
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

4°C, sealed storage, away from moisture

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Publications (2)

All

Sort by:

Journal Impact Factor

Int J Mol Sci

Combined Therapy Targeting MET and Pro-HGF Activation Shows Significant Therapeutic Effect Against Liver Metastasis of CRPC. [Abstract]

2025 Mar 5;26(5):2308. PMID: 40076928
Biomedicines

Phosphorylation of MET Is Upregulated in Metastatic Sites of Renal Cell Carcinoma: Possible Role of MET and Hepatocyte Growth Factor Activation-Targeted Combined Therapy. [Abstract]

2025 Mar 28;13(4):811. PMID: 40299443

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 125 mg/mL (234.26 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.8741 mL

9.3705 mL

18.7410 mL

5 mM

0.3748 mL

1.8741 mL

3.7482 mL

10 mM

0.1874 mL

0.9370 mL

1.8741 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.08 mg/mL (3.90 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.08 mg/mL (3.90 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.08 mg/mL (3.90 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (274 KB)
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Owusu BY, et al. Inhibition of pro-HGF activation by SRI31215, a novel approach to block oncogenic HGF/MET signaling. Oncotarget. 2016 May 17;7(20):29492-506. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	1.8741 mL	9.3705 mL	18.7410 mL	46.8524 mL
	5 mM	0.3748 mL	1.8741 mL	3.7482 mL	9.3705 mL
	10 mM	0.1874 mL	0.9370 mL	1.8741 mL	4.6852 mL
	15 mM	0.1249 mL	0.6247 mL	1.2494 mL	3.1235 mL
	20 mM	0.0937 mL	0.4685 mL	0.9370 mL	2.3426 mL
	25 mM	0.0750 mL	0.3748 mL	0.7496 mL	1.8741 mL
	30 mM	0.0625 mL	0.3123 mL	0.6247 mL	1.5617 mL
	40 mM	0.0469 mL	0.2343 mL	0.4685 mL	1.1713 mL
	50 mM	0.0375 mL	0.1874 mL	0.3748 mL	0.9370 mL
	60 mM	0.0312 mL	0.1562 mL	0.3123 mL	0.7809 mL
	80 mM	0.0234 mL	0.1171 mL	0.2343 mL	0.5857 mL
	100 mM	0.0187 mL	0.0937 mL	0.1874 mL	0.4685 mL

Bioz

Keywords

SRI 31215 TFA

2 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

SRI 31215 TFA

Publications Citing Use of MedChemExpress (MCE) SRI 31215 TFA